Get to Know Norman Sussman, Chief Medical Officer at DURECT
BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases.
Read the post
Let’s Get to Know Paula Ragan, CEO and President of X4 Pharmaceuticals
BioSpace spoke with Paula Ragan, CEO and President of X4 Pharmaceuticals, a company focused on restoring healthy immune system function in people with rare diseases.
Read the post
What Is Gene Editing? How It Works In 2-Minutes
Gene therapy, stem cell therapy, CAR T, cell therapy, and gene editing are all forms of genomic medicine1 - an approach to cure and treat human diseases that uses human biology rather than chemical compounds made in the lab.
Read the post
Importance of Interoperability During COVID-19 | Smile CDR
The COVID-19 pandemic is far from over, yet with vaccination programs well underway and an end to rising infections in sight, we now have the opportunity to assess...
Read the post
Technology Transfer, A Catalyst For Gene Therapy Startups | The Spark Therapeutics Example
The ability to consistently bring treatments and cures to market depends upon a company’s capacity to create and sustain a successful product development pipeline.
Read the post
Rare Disease Math
In years past, there were no viable therapies for rare diseases. Today, the barrier to viable therapies is the cost associated with their development.
Read the post
What Is a Viral Vector?
You have something you want delivered to a defended location. A viral vector is one way to fulfill this purpose.
Read the post
Biotech & Human Insulin
Did you know that insulin you're using was produced in a lab by E. coli?!
Read the post
What Is Gene Therapy? How It Works In 2-Minutes
Written for and originally published on AGT Big Picture Gene therapy, stem cell therapy, CAR-T, cell therapy and gene editing […]
Read the post